Actualités Intelgenx Technologies Corp - IGX | Actions Toronto Stock Exchange

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

MONTREAL, July 19, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OTC:...

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of...

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of...

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies...

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”...

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”...

IntelGenx Announces Voting Results on Election of Directors

SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT...

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT...

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT...

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT...

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

IntelGenx Launches Preferred Share Regulation A Offering

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

SAINT LAURENT, Quebec, Feb. 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Intelgenx Technologies Corp (IGX)

Votre Hub pour des idées et discussions en direct en temps réel

IGX Actualités

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

IntelGenx Launches Preferred Share Regulation A Offering

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Intelgenx Technologies Corp (IGX) Actualités

Intelgenx Technologies Corp (IGX)

Votre Hub pour des idées et discussions en direct en temps réel

IGX Actualités

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

IntelGenx Launches Preferred Share Regulation A Offering

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application